Fulcrum Therapeutics (FULC) Current Leases (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Current Leases for 9 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Leases rose 9.81% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $2.5 million (up 9.81% YoY), while the FY2025 annual figure was $2.4 million, up 9.97% from the prior year.
• Current Leases climbed to $2.5 million in Q2 2026 per FULC's latest filing, from $2.5 million in the prior quarter.
• Across five years, Current Leases topped out at $2.7 million in Q1 2023 and bottomed at $2.0 million in Q1 2024.
• Historically, Current Leases has averaged $2.4 million across 5 years, with a median of $2.4 million in 2023.
• Annual changes were most pronounced in 2022 — Current Leases jumped 60550.0% — and 2024, when it retreated 23.7%.
• Fulcrum Therapeutics' Current Leases stood at $2.6 million in 2022, then declined by 15.76% to $2.2 million in 2023, then fell by 0.27% to $2.2 million in 2024, then rose by 9.97% to $2.4 million in 2025, then climbed by 4.74% to $2.5 million in 2026.
• Business Quant data shows FULC's Current Leases at $2.5 million in Q2 2026, $2.5 million in Q1 2026, and $2.4 million in Q4 2025.